drugset / Trial / NCT03360461

EMI-137 in Laparoscopic Colonic Resections

NCT03360461 ↗

NaSingle-groupOpen-labelTreatment

Summary

EMI-137 in laparoscopic colonic resections is a single-centre stage IIa developmental study. Ten adult participants with a diagnosis of colon adenocarcinoma undergoing laparoscopic colonic will be recruited to the trial. Participants will receive a single intravenous dose of the IMP - EMI-137 1 to 3 hours before surgery. The ability of EMI-137 to produce visible intra-operative fluorescence of primary colon cancer and lymph node metastases will be explored and evaluated.

Timeline

Start
2018-02-14
Primary completion
2020-02-14
Completion
2020-03-14

Drugs

EvaluationDrugModalityDoseRoute
Subject EMI-137 Peptide 0.02 mg/kg Intravenous
Subject EMI-137 Peptide 0.13 mg/kg Intravenous